ONC vs. RGEN: BeOne Medicines vs. Repligen Stock Comparison
How do BeOne Medicines (ONC) and Repligen (RGEN) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
BeOne Medicines (ONC) and Repligen (RGEN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ONC is classified in Biotechnology while RGEN is classified in Life Sciences Tools & Services.
Repligen (RGEN) trades as ordinary local shares, while BeOne Medicines (ONC) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | ONC | RGEN |
|---|---|---|
| Name | BeOne Medicines Ltd. American Depositary Shares | Repligen Corporation |
| Country/Region | Switzerland | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| GICS Sub-Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 46.49 billion USD | 11.09 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | February 3, 2016 | April 29, 1986 |
| Security Type | ADR | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ONC | RGEN |
|---|---|---|
| Total Return (1Y) | 30.59% | 23.28% |
| Total Return (3Y, Annualized) | 30.15% | 6.20% |
| Total Return (5Y, Annualized) | 2.48% | -8.41% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ONC | RGEN |
|---|---|---|
| Volatility (1Y, Annualized) | 35.90% | 46.73% |
| Beta (5Y) | 0.59 | 1.11 |
| Max Drawdown (5Y) | -68.89% | -64.67% |
| Avg. Volume (3M) | 405.29K | 1.18M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ONC | RGEN |
|---|---|---|
| Sharpe Ratio (1Y) | 0.73 | 0.41 |
| Sortino Ratio (1Y) | 1.15 | 0.60 |
Profitability
ROE (TTM)
Repligen (RGEN) reports a negative ROE of -0.57%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile BeOne Medicines (ONC) reports 18.40%, ranking against industry peers normally.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
18.40%
- Max
- 109.18%
- ONC
- 18.40%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-0.57%
- Max
- 109.18%
- Q3
- 6.23%
- RGEN
- -0.57%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Repligen (RGEN) reports a negative net margin of -1.47%, usually indicating a net loss over the period. Meanwhile BeOne Medicines (ONC) reports 13.86%, ranking against industry peers normally.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.86%
- Max
- 18.05%
- ONC
- 13.86%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
-1.47%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- RGEN
- -1.47%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
BeOne Medicines (ONC) at 22.15% operates in the top operating margin quartile, ahead of Repligen (RGEN) at 6.19%, which runs around its industry’s norm.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.15%
- Max
- 83.12%
- ONC
- 22.15%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.19%
- Max
- 83.12%
- Q3
- 14.77%
- RGEN
- 6.19%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ONC | RGEN |
|---|---|---|
| ROE (TTM) | 18.40% | -0.57% |
| ROA (TTM) | 8.42% | 1.40% |
| Net Margin (TTM) | 13.86% | -1.47% |
| Operating Margin (TTM) | 22.15% | 6.19% |
| Gross Margin (TTM) | 89.39% | 53.77% |
Growth
Revenue Growth
Both BeOne Medicines (ONC) at 40.23% and Repligen (RGEN) at 16.36% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Neither BeOne Medicines (ONC) nor Repligen (RGEN) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | ONC | RGEN |
|---|---|---|
| Revenue Growth (YoY) | 40.23% | 16.36% |
| Revenue Growth (3Y CAGR) | 55.69% | -2.70% |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -35.73% |
Financial Strength
Current Ratio (MRQ)
Both BeOne Medicines (ONC) at 3.55 and Repligen (RGEN) at 9.88 carry current ratio within their industries’ typical mid-ranges, suggesting balanced short-term liquidity relative to peers.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.55
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- ONC
- 3.55
- Q1
- 2.47
- Min
- 0.10
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.88
- Max
- 25.13
- Q3
- 12.13
- RGEN
- 9.88
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Both BeOne Medicines (ONC) at 0.35 and Repligen (RGEN) at 0.33 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.35
- Max
- 1.42
- Q3
- 0.65
- ONC
- 0.35
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.33
- Max
- 1.42
- Q3
- 0.65
- RGEN
- 0.33
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ONC | RGEN |
|---|---|---|
| Current Ratio (MRQ) | 3.55 | 9.88 |
| Debt / Equity (MRQ) | 0.35 | 0.33 |
| Net Debt / EBITDA | -2.80 | -1.19 |
Dividends
Dividend Yield (TTM)
Neither BeOne Medicines (ONC) nor Repligen (RGEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- RGEN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither BeOne Medicines (ONC) nor Repligen (RGEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ONC
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- RGEN
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ONC | RGEN |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
An earnings multiple is available for just one side: BeOne Medicines (ONC) trades at 52.17 times trailing earnings, ranked against its peers, while Repligen (RGEN) has no P/E ratio this period.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
52.17
- Max
- 85.34
- ONC
- 52.17
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- RGEN
- --
P/S Ratio (TTM)
On P/S ratio, both BeOne Medicines (ONC) at 7.04 and Repligen (RGEN) at 13.77 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.04
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- ONC
- 7.04
- Q1
- 3.01
- Min
- 0.01
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.77
- Max
- 58.18
- Q3
- 25.77
- RGEN
- 13.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
Repligen (RGEN) at 4.70 is valued about in line with its industry on P/B ratio, while BeOne Medicines (ONC) at 7.98 carries an above-peer premium to book — ONC is pricier on assets.
ONC
Pharmaceuticals, Biotechnology & Life Sciences industry group
7.98
- Max
- 13.53
- ONC
- 7.98
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
RGEN
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.70
- Max
- 13.53
- Q3
- 6.54
- RGEN
- 4.70
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ONC | RGEN |
|---|---|---|
| P/E Ratio (TTM) | 52.17 | -- |
| P/S Ratio (TTM) | 7.04 | 13.77 |
| P/B Ratio (MRQ) | 7.98 | 4.70 |
| Free Cash Flow Yield (TTM) | 2.21% | 1.01% |